Search Results

Edesa Biotech, Inc. announced today that Edesa management plans to participate in the following upcoming investor conferences.

Edesa Biotech, Inc. reported financial results for the three and six months ended March 31, 2024 and provided an update on its business.

Edesa Biotech, Inc. announced today that its first-in-class drug candidate has been selected by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, for evaluation in a U.S. government-funded clinical study.

Edesa Biotech, Inc. announced today that the company will participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference scheduled for April 16-17, 2024 in Toronto, Ontario.

Edesa Biotech, Inc. announced today that company management will participate in the Barclays 26th Annual Global Healthcare Conference, which is being held in Miami, Florida, from March 12-14, 2024.

Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that the company will participate in a Fireside Chat and host one-on-one meetings at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference on March 28, 2024.

Edesa Biotech, Inc. reported financial results for the three months ended December 31, 2023 and provided an update on its business.

Edesa Biotech, Inc. announced that the company plans to participate in the American Contact Dermatitis Society Annual Meeting on March 7, 2024 and the American Academy of Dermatology Annual Meeting from March 8-12, 2024 in San Diego, California.